ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
Rhea-AI Summary
ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical stage oncology company, has announced its participation in three upcoming investor conferences in September 2024:
- 2024 Wells Fargo Healthcare Conference on September 5 at 8:00 a.m. ET
- Baird 2024 Global Healthcare Conference on September 10 at 10:50 a.m. ET (for conference attendees only)
- 2024 Cantor Global Healthcare Conference on September 19 at 8:35 a.m. ET
The company will participate in fireside chats at each event. Live webcasts for the Wells Fargo and Cantor conferences will be available on ORIC's website, with replays accessible for 90 days after the events. This engagement demonstrates ORIC's commitment to investor relations and showcasing its progress in developing treatments for therapeutic resistance in oncology.
Positive
- None.
Negative
- None.
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in September:
- 2024 Wells Fargo Healthcare Conference – Participating in a fireside chat on Thursday, September 5, 2024, at 8:00 a.m. ET
- Baird 2024 Global Healthcare Conference (Available to conference attendees only) – Participating in a fireside chat on Tuesday, September 10, 2024, at 10:50 a.m. ET.
- 2024 Cantor Global Healthcare Conference – Participating in a fireside chat on Thursday, September 19, 2024, at 8:35 a.m. ET
Live webcasts of the Wells Fargo and Cantor discussions will be available through the investor section of the company’s website at www.oricpharma.com. Replays of the webcasts will be available for 90 days following the events.
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (3) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma. Beyond these three product candidates, ORIC® is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.
Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com
FAQ
What investor conferences will ORIC Pharmaceuticals participate in during September 2024?
Will ORIC Pharmaceuticals' conference presentations be available for public viewing?
What is the focus of ORIC Pharmaceuticals' research and development?
When is ORIC Pharmaceuticals scheduled to present at the 2024 Wells Fargo Healthcare Conference?
